Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical methods for supercoiled pNDA production.

John Ballantyne1

  • 1Aldevron, LLC, Fargo, NC, USA.

Methods in Molecular Medicine
|September 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.

Journal of virology·2021
Same author

Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival.

Journal for immunotherapy of cancer·2020
Same author

Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines.

Scientific reports·2020
Same author

Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice.

Antiviral research·2017
Same author

Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Journal of virology·2016
Same author

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

PLoS neglected tropical diseases·2015

Researchers can now purify 100-200 mg of plasmid DNA (pDNA) in-house using adaptable methods. These techniques balance simplicity and efficiency for preclinical research needs.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Biopharmaceutical Manufacturing

Background:

  • Growing demand for high-purity plasmid DNA (pDNA) for preclinical applications.
  • Existing production methods may not meet new, stringent specifications.
  • Need for scalable, in-house purification strategies.

Purpose of the Study:

  • To present practical methods for purifying 100-200 mg of pDNA in-house.
  • To offer adaptable unit processes for researchers and manufacturers.
  • To address the compromise between simple and advanced purification techniques.

Main Methods:

  • Utilizing adaptable unit processes for pDNA purification.
  • Balancing gravity-flow/vacuum techniques with intermediate-scale chromatography.

Related Experiment Videos

  • Considering feedstock quality and desired purity levels for method selection.

    • Main Results:

    • Realistic methodologies for in-house pDNA purification (100-200 mg) are provided.
    • The described methods offer a compromise for efficient purification at this scale.
    • Unit processes can be tailored to specific research and manufacturing needs.

    Conclusions:

    • In-house pDNA purification is feasible at the 100-200 mg scale.
    • Adaptable methodologies enable researchers to meet demanding specifications.
    • Optimized purification strategies are crucial for advancing preclinical research.